Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Pharma Discusses How to Reframe Value in Era of Precision Medicine, Combinations
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Currently Reading
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer

The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.


The breast cancer community is very excited about the approval of atezolimuab for the treatment of triple-negative breast cancer, explained Lee Schwartzberg, MD, FACP, executive director, West Cancer Center.

Transcript

The FDA recently approved the first immunotherapy regimen for breast cancer with the approval of atezolizumab. How important was this approval for a type of breast cancer that didn’t have many other treatment options?

We’re very excited about the approval of atezolizumab in triple-negative breast cancer. This is a disease that has a poor outcome, and of all the subgroups of breast cancer, this one has the worst prognosis when it becomes metastatic. And also, we’ve been very excited about immuno-oncology (IO) drugs in many other types of cancers.

We’ve been waiting in breast cancer to get an IO drug approved, and now we have atezolizumab with abraxane for triple-negative breast cancer patients that are PD-L1 [programmed death ligand-1] positive—that’s the biomarker that distinguishes those that are going to respond. We’ve seen some great results with response rates and some intriguing preliminary overall survival data, which will have to continue to mature. I think the breast cancer community is very excited about having an IO options finally to treat our patients, particularly for this very difficult group of patients to treat.

Do you think there is a future for more immunotherapy in breast cancer?

Yes—we’re going to be seeing many other trials of immunotherapy in breast cancer. In the metastatic setting, in the same type of setting that atezolizumab has been approved, there are other partner drugs that are being tested with atezolizumab. Some of the other PD-1 and PD-L1 inhibitors are also being tested in the first-line for metastatic disease, and we’ve already learned that PD-1 inhibitors in breast cancer work better the earlier that you use them before the immune system is exhausted. That’s led to studies of using immunotherapy in the neoadjuvant or adjuvant setting. Those studies are ongoing, but many of us are very excited that that might be the ultimate best use of immunotherapy in breast cancer and preventing recurrence of disease rather than treating it.

 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up